Neogenomics, Inc. · NASDAQ:NEO
Neogenomics — Merger or Acquisition (October 2018)
11 slides from Neogenomics's merger presentation, Oct 23, 2018
Slide 1: NeoGenomics Acquisition of Genoptix
NeoGenomics Acquisition of Genoptix October 23, 2018
Slide 2: Forward-Looking Statements
Forward‐Looking Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of
Slide 3: A New Standard in Oncology Testing
A New Standard in Oncology Testing NeoGenomics Well established as a leading provider of oncology testing for pathologists and hospitals Genoptix Unprecedented reach to all customer segments Broadest and deepest test menu in the Industry Outstanding reputation Deep knowledge of community oncol
Slide 4: Bends the Curve
Bends the Curve Potential Revenue $500 • Incremental revenue of ~$85M • Pro form combined revenue of ~$350M $400 • ~$25 million of cost synergies • ~25% EBITDA on incremental revenue by end of year three $300 $200 2018 2019 2020 2021 Pre Post Potential EBITDA $110 $90 $70 Note: graphs and estimates
Slide 5: Genoptix Overview
Genoptix Overview • Leading oncology‐focused lab • Outstanding reputation and relationship with community oncology practices • Cases managed by specialized pathologists and hematopathologists • Experience with complex and challenging disease states • 170,000 test reports issued in 2017 • Located in
Slide 6: Expands Reach into Oncology Practices
Expands Reach into Oncology Practices Significant opportunity Genoptix is well established in for growth this market segment $2.5 billion revenue 40 person oncologist‐focused sales opportunity force (5x larger than NeoGenomics’ current oncology team) >2,000 independent, Customized reports specifical
Slide 7: Leverages Best Offerings
Leverages Best Offerings MANAGED CARE CUSTOMIZED EXTENSIVE PHARMA NATIONAL AND GPO REPORTING TEST MENU SERVICES FOOTPRINT CONTRACTS NeoGenomics’ test Synergistic With operations on NeoGenomics Genoptix has a menu includes many pharma services both coasts, has a broad suite of tests that Genoptix bus
Slide 8: COMPASS® and CHART®
COMPASS® and CHART® COMPASS: comprehensive, hematopathologist‐directed, integrated assessment report • Customized workflow on each patient case to provide a disease‐specific evaluation based on up‐to‐date guidelines • Actionable diagnosis in a one‐page correlation report • Consultation with assigned
Slide 9: Creates Innovative Value Proposition
Creates Innovative Value Proposition NEOGENOMICS • Can provide both technical and professional services (including customized consults and reports) to oncologist, when preferred • ONCOLOGIST Can provide “tech‐only” services to pathologist when Expanded referral preferred by oncologist options with a
Slide 10: Raises the Bar
Raises the Bar • Significantly expands reach into oncology practices • Creates unique value proposition for oncologists, pathologists, hospitals, payors and patients • Enhances and leverages combined product offering • Increases opportunity for coordination between oncologists and pathologists withi
Slide 11: All rights reserved. All other trademarks are the property of their respective owners.
© 2018 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property of their respective owners.